Investor Relations

Print   Email  
Stock price graph
     

Ocera is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's lead program, OCR-002, is an ammonia scavenger designed to treat hyperammonemia (elevated ammonia in the blood) and associated hepatic encephalopathy, a complication of patients with liver cirrhosis.

View all »   RSSRecent Releases

Feb 23, 2015
Ocera Therapeutics to Present at 35th Annual Cowen and Company Health Care Conference

Feb 18, 2015
Ocera Announces Preliminary Topline Results From Phase 2a Investigator-Sponsored Study of OCR-002

View all »Events & Presentations

Mar 2, 2015 at 4:50 PM ET
Cowen and Company Annual Health Care Conference

Investors